Multivariate random intercept linear regression models of NVP concentrations as predictors of log transformed transaminase levels at the next visit.

<p>Multivariate random intercept linear regression models of NVP concentrations as predictors of log transformed transaminase levels at the next visit.</p

Bar graph of multivariate-adjusted odds ratio of viral suppression by quartile of concentration of NVP in hair.

<p>Bar graph of multivariate-adjusted odds ratio of viral suppression by quartile of concentration of NVP in hair.</p

Adjusted* prevalence risk ratios (PRs) of detectable plasma HIV RNA and mean differences in plasma HIV RNA and CD4+ T cell counts (from the cross-sectional log binomial and linear regression models at the 3^rd visit) by degree of HSV-2 clinical activity.

<p>Note: CI, confidence interval; PR, prevalence ratio; <i>P</i>, p-value; SR GH, self reported genital herpes; L-V, lesion-visit; ^*adjusted for baseline CD4+ T cell count, herpes medications and type of antiretroviral therapy used at the visit, age, race, lifetime number of sexual partners, injection and noninjection drug use; ^†positive self report of genital herpes only; ^‡number of visits with lesions.</p

Characteristics of women contributing to the nevirapine (NVP) hair analysis (n = 271 individuals).

<p>Note. Data are number (%) of study participants unless otherwise indicated.</p><p>N = number</p><p>^aMedian number of visits per patient was 3 (range, 1–11); 81 women had 1 visit; 37 had 2 visits; 27 had 3 visits; 28 had 4 visits; 19 had 5 visits; 16 had 6 visits; 14 had 7 visits; 8 had 8 visits; 27 had 9 visits; 9 had 10 visits; 5 had 11 visits.</p><p>^bThreshold of detection, 80 copies/mL.</p><p>Characteristics of women contributing to the nevirapine (NVP) hair analysis (n = 271 individuals).</p

Adjusted* prevalence risk ratios (PRs) of detectable plasma HIV RNA and mean differences in plasma HIV RNA and CD4+ T cell counts (from the GEE analysis with robust variance estimation) by degree of HSV-2 clinical activity.

<p>Note: GEE, Generalized Estimating Equations; CI, confidence interval; PR, prevalence ratio; <i>P</i>, p-value; SR GH, self reported genital herpes; L-V, lesion-visit; ^*adjusted for baseline CD4+ T cell count, herpes medications and type of antiretroviral therapy used at the visit, age, race, lifetime number of sexual partners, injection and noninjection drug use; ^†positive self report of genital herpes only; ^‡number of visits with lesions.</p

Crude prevalence risk ratios (PRs) of detectable plasma HIV RNA and mean differences in plasma HIV RNA and CD4+ T cell counts (from the GEE analysis with robust variance estimation) by degree of HSV-2 clinical activity.

<p>Note: GEE, Generalized Estimating Equations; CI, confidence interval; PR, prevalence ratio; <i>P</i>, p-value; SR GH, self reported genital herpes; L-V, lesion-visit; ^†positive self report of genital herpes only; ^‡number of visits with lesions.</p

Flowchart of study participants and description of exposure groups.

<p>Flowchart of study participants and description of exposure groups.</p

Geographic distribution of North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) clinical sites contributing to these analyses.

<p>Non-contributing sites were interval cohorts, Canadian cohorts (excluded due to the focus on US clinical care populations), or cohorts not currently contributing HIV primary care encounter data to the NA-ACCORD.</p

Comparison of baseline HIV disease markers by study groups.

<p>Note: IQR, interquartile range; SR GH, self reported genital herpes; L-V, lesion-visit; ^†positive self report of genital herpes only; ^‡number of visits with lesions.</p><p>* <i>P</i> - <i>p-value</i> for overall comparison of symptomatic group vs. asymptomatic group.</p><p>** among women with HIV pVL >4,000 copies/ml.</p

Comparison of demographic, risk and clinical characteristics by study groups.

<p>Note: IQR, interquartile range; <i>P</i>, p-value.</p